BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’
Boston Scientific (BSX) lowered its full-year adjusted earnings outlook to $3.16-$3.18 per share and expects Q4 sales to decline 1-3%. Q3 sales rose 1.5% to $5.14B, beating estimates. The company cited a cybersecurity attack for disruptions. Shares fell 8%, hitting 4-year lows. CEO remains confident in long-term strategy.
How this was made
The 30-second read
Why it matters
The guidance cut is the primary catalyst for the stock move; the cyber incident adds a risk overlay.
Market read
First‑time disclosure of lower earnings guidance and Q4 sales decline for a large‑cap med‑tech firm, driving immediate price action.
What to watch
CEO's confidence in long‑term strategy and pipeline of new technologies could support a rebound once the disruption clears.
Background
Boston Scientific disclosed a cyber‑attack that disrupted manufacturing and order processing, which may have contributed to the weaker outlook.
Ticker impact
Boston Scientific lowered its full-year adjusted earnings outlook to $3.16‑$3.18 per share and warned Q4 sales will decline 1‑3%, triggering an 8% share drop.
likely further pressure as investors price in weaker outlook
The new guidance is materially below prior expectations and was announced alongside an 8% intraday sell‑off, indicating fresh negative sentiment.
Market effects
Medical device sector may see broader pressure as the outlook hints at demand softness.
U.S. healthcare stocks could face short‑term weakness.
Limited to investors with exposure to Boston Scientific and related med‑tech peers.
Counterpoint
If the cybersecurity incident is resolved quickly, the sales dip may be temporary, offering a buying opportunity at lower levels.
Key entities
- ExecutiveMike Mahoney
CEO of Boston Scientific, reaffirmed confidence in long‑term strategy.
